FDA Releases Alexion Response to Form 483 on Microbial Contaminations
In a rare move, the FDA has publically released Alexion Pharmaceuticals’ response to a Form 483 following inspection of its US site and the discovery of microbial contamination.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs